[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100642372":3},{"organization":4,"armGroups":7,"interventions":24,"overallOfficials":18,"centralContacts":40,"locations":18,"responsibleParty":49,"collaborators":18,"id":51,"slug":52,"hasResults":53,"nctId":54,"briefTitle":55,"officialTitle":56,"acronym":57,"eligibilityCriteria":58,"healthyVolunteers":53,"sex":59,"minAge":60,"maxAge":18,"enrollmentInfo":61,"targetDuration":18,"studyType":64,"phases":65,"briefSummary":67,"conditions":68,"keywords":18,"overallStatus":70,"whyStopped":18,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":18},{"fullName":5,"class":6},"Verastem, Inc.","INDUSTRY",[8,16,20],{"label":9,"type":10,"description":11,"interventionNames":12},"VS-7375 Monotherapy or Preferred Combination in 2L+ CRC","EXPERIMENTAL","Participants randomized to a treatment in 2:1 ratio",[13,14,15],"Drug: VS-7375","Drug: cetuximab","Drug: panitumumab",{"label":17,"type":10,"description":18,"interventionNames":19},"VS-7375 with chosen regimen in 2L+ CRC",null,[13,14,15],{"label":21,"type":10,"description":18,"interventionNames":22},"VS-7375 + cetuximab and mFOLFOX in 1L CRC",[23],"Drug: Cetuximab + mFOLFOX6",[25,30,34,37],{"type":26,"name":27,"description":28,"armGroupLabels":29,"otherNames":18},"DRUG","VS-7375","Taken by mouth",[9,17],{"type":26,"name":31,"description":32,"armGroupLabels":33,"otherNames":18},"cetuximab","Intravenous infusion",[9,17],{"type":26,"name":35,"description":32,"armGroupLabels":36,"otherNames":18},"panitumumab",[9,17],{"type":26,"name":38,"description":32,"armGroupLabels":39,"otherNames":18},"Cetuximab + mFOLFOX6",[21],[41,46],{"name":42,"role":43,"phone":44,"phoneExt":18,"email":45},"Verastem Call Center","CONTACT","7812924204","VS-7375-203TrialSupport@verastem.com",{"name":47,"role":43,"phone":18,"phoneExt":18,"email":48},"Luke Chung, MD","VS-7375-203Medical@verastem.com",{"type":50,"investigatorFullName":18,"investigatorTitle":18,"investigatorAffiliation":18,"oldNameTitle":18,"oldOrganization":18},"SPONSOR","100642372","phase-2-a-phase-2-study-of-vs-7375-in-patients-with-kras-g12d-mutated-colorectal-cancer-100642372",false,"NCT07659795","A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Colorectal Cancer","A Phase 2, Open-label Study of VS-7375, an Oral KRAS G12D (ON\u002FOFF) Inhibitor, With and Without an Anti-EGFR Antibody, and With an Anti-EGFR Antibody and Chemotherapy, in Patients With Metastatic KRAS G12D-Mutated Colorectal Adenocarcinoma (TARGET-D 203)","TARGET-D 203","Inclusion Criteria:\n\n* Histopathology confirmed metastatic CRC\n* Measurable disease per RECIST 1.1\n* Local testing confirmed KRAS G12D mutation (tissue required for confirmatory central testing)\n* ECOG PS=0 or 1\n\n  2L+ patients:\n* Must have received at least 1 standard chemotherapy for metastatic colorectal adenocarcinoma\n* Have documented disease progression during or following their most recent prior line of therapy\n* Have either stable disease, partial response (PR), or complete response (CR) by RECIST v1.1 as the best overall response (BOR) during at least 1 prior systemic therapy.\n\n  1L patients:\n* Treatment-naïve or received no more than 1 cycle of standard systemic therapy for metastatic disease.\n\nExclusion Criteria:\n\n* Have any other documented co-existing common RAS mutation(s)\n* Prior anti-cancer Tx within 4 weeks or drug-specific timeline within first treatment dose, whichever shorter\n* Major surgery within 4 weeks of first treatment dose\n* Radiation therapy (RT) within 1 week of first treatment dose\n* Receipt of prior direct RAS inhibitor\n* Receipt of more than 1 investigational therapy\n* Untreated or symptomatic CNS metastasis\n* Receipt of strong CYP3A4 inhibitor\u002Finducer or CYP3A4 sensitive substrates with narrow therapeutic index within 14 days or drug-specific timeline within first treatment dose, whichever is shorter\n* Receipt of PPI or H2 blocker within 5 days\n* Inability to swallow oral medication\n* Other protocol-defined inclusion\u002Fexclusion criteria may apply","ALL","18 Years",{"count":62,"type":63},150,"ESTIMATED","INTERVENTIONAL",[66],"PHASE2","This study will assess the safety and efficacy of VS-7375 alone and in combination with cetuximab or panitumumab and cetuximab plus mFOLFOX in patients with metastatic KRAS G12D - mutated Colorectal Cancer",[69],"Colorectal Cancer","NOT_YET_RECRUITING","2026-06-15",{"date":73,"type":74},"2026-06-22","ACTUAL",{"date":76,"type":63},"2026-06",{"date":78,"type":63},"2028-12",{"name":5,"class":6}]